Eurobio Scientific reported first-half 2026 revenue of €84.5 million, up 5% from €80.7 million a year earlier, as the French in-vitro diagnostics group continued its strategic shift toward proprietary products and international markets. Proprietary product sales grew 10% to €31.3 million, representing 37% of total revenue, while distribution revenue edged up 2% to €53.2 million but fell 5% on a like-for-like basis due to the end of One Lambda tenders. International sales accounted for 47% of revenue, driven by acquisitions and strong growth at GenDx in the US and Canada. The company also disclosed that its distribution contract with South Korea’s Seegene, which generated €48 million in full-year 2025 revenue, will end on 31 December 2026, with Seegene planning to enter the French market directly; Seegene-related revenue reached €25.6 million in the first half, up 12%.
Eurobio Scientific SAEurobio reported 5% revenue growth, with proprietary product sales up 10% and strong international growth at GenDx.
Seegene IncSeegene's distribution contract with Eurobio ends Dec 2026, and Seegene plans to enter French market directly, potentially increasing competition.